<DOC>
	<DOCNO>NCT01474200</DOCNO>
	<brief_summary>The purpose research determine patient few Heart Failure ( HF ) event receive Aquapheresis ( AQ ) therapy compare intravenous ( IV ) diuretics 90 day discharge hospital . Heart Failure event define return hospital , clinic emergency department ( ED ) treatment HF symptom .</brief_summary>
	<brief_title>Study Heart Failure Hospitalizations After Aquapheresis Therapy Compared Intravenous ( IV ) Diuretic Treatment</brief_title>
	<detailed_description>The aim propose AVOID-HF study confirm expand finding fluid removal AQ reduce HF rehospitalizations 90 day well length HF rehospitalizations . In `` Ultrafiltration Versus Intravenous Diuretics Patients Hospitalized Acute Decompensated Heart Failure '' ( UNLOAD ) study , 90 day HF re-hospitalizations pre-specified secondary end-points . AVOID-HF design primary end-point determine AQ reduce number HF event ( Rehospitalization unscheduled outpatient emergency room treatment HF ) discharge index hospitalization compare IV loop diuretic . AVOID also explore day alive hospital secondary end-point , do UNLOAD . In word , AVOID-HF study go beyond study amount fluid removal explore whether modality fluid removal influence HF outcome .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
	<criteria>1 . 18 year age old 2 . Male nonpregnant female patient 3 . Admitted hospital primary diagnosis acute decompensated heart failure ( ADHF ) 4 . On regularly schedule oral loop diuretic prior admission 5 . Fluid overload manifest least two follow : 1 . Pitting edema ( 2+ ) low extremity 2 . Jugular venous distention &gt; 8 cm 3 . Pulmonary edema pleural effusion chest xray 4 . Paroxysmal nocturnal dyspnea ≥ two pillow orthopnea 5 . Respiration rate ≥ 20 per minute . 6 . Have receive ≤ 2 IV loop diuretic dose randomization 7 . Must able enrol trial ≤ 24 hour admission hospital . 8 . Provide write informed consent form require local IRB ( Institutional Review Board ) 1 . Acute coronary syndrome 2 . Renal insufficiency sCr ≥ 3.0 mg/dl plan renal replacement therapy 3 . Systolic blood pressure &lt; 90 mmHg time enrollment 4 . Pulmonary Arterial Hypertension secondary leave heart disease 5 . Contraindications systemic anticoagulation 6 . Hematocrit &gt; 45 % 7 . Inability obtain venous access 8 . Hemodynamic instability severe enough require IV positive inotropic agent , IV vasodilator 9 . Use iodinate radiocontrast material within previous 72 hour plan study require IV contrast current hospitalization 10 . Severe concomitant disease expect prolong hospitalization 11 . Severe concomitant disease expect cause death ≤ 90 day 12 . Sepsis ongoing systemic infection 13 . Severe uncorrected valvular stenosis 14 . Active myocarditis 15 . Hypertrophic obstructive cardiomyopathy 16 . Constrictive pericarditis restrictive cardiomyopathy 17 . Liver cirrhosis 18 . Previous solid organ transplant 19 . Requirement mechanical ventilatory support 20 . Presence mechanical circulatory support device 21 . Unwillingness inability complete follow 22 . Active drug ETOH substance abuse 23 . Participating another interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Ultrafiltration</keyword>
	<keyword>Aquapheresis</keyword>
	<keyword>Diuretics</keyword>
	<keyword>Loop Diuretics</keyword>
	<keyword>Aquadex Flexflow System</keyword>
	<keyword>Gambro UF Solutions</keyword>
</DOC>